By Katherine Hamilton
Simulations Plus posted a lower profit for its first fiscal quarter of 2025 as the cost of its software and services rose.
The company, which provides modeling and simulation software to biopharmaceutical companies, posted a profit of $206,000, or 1 cent a share, in the three months ended Nov. 30, compared with $2 million, or 10 cents a share, a year earlier.
Stripping out certain one-time items, adjusted per-share earnings were 17 cents, in line with what FactSet analysts expected.
Revenue rose 31% to $18.9 million. Analysts surveyed by FactSet forecast revenue of $18.8 million.
Simulations Plus reiterated its 2025 guidance of $90 million to $93 million in revenue.
Costs of revenues for software and services roughly doubled year-over-year. Services revenue increased 19%, but faced some challenges because client-driven data was postponed, the company said.
"Overall, our team achieved solid results despite ongoing funding challenges and cost constraints in the pharma and biotech sectors," said chief executive Shawn O'Connor.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
January 07, 2025 16:36 ET (21:36 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。